A groundbreaking study in Nature Structural & Molecular Biology (Mighell & Lehner, 2025) shows that a single drug can rescue the function of nearly all disease-causing mutations in a key human receptor. This discovery could change how we treat many rare diseases (Mighell & Lehner, 2025).

Why This Matters

Most rare diseases are caused by changes in a single gene, and many of those changes—called missense mutations—make proteins unstable. Unstable proteins can’t fold correctly and often get destroyed by the cell before they can do their job (Ross et al., 2023).

Until now, scientists believed that each mutation would need its own tailored therapy. But this new research shows that one drug—a small molecule called tolvaptan—can stabilize hundreds of different mutations in a protein called the vasopressin 2 receptor (V2R). Mutations in V2R cause nephrogenic diabetes insipidus (NDI), a rare condition where the kidneys can’t concentrate urine (Bockenhauer & Bichet, 2015).

What the Study Found

Researchers created over 7,000 versions of the V2R protein, each with a single mutation. They then tested whether those proteins could reach the cell surface, which is necessary for the receptor to work.

  • Over half of the mutations made the protein unstable and prevented it from reaching the cell surface.
  • When treated with tolvaptan, 87% of the unstable versions were rescued—meaning the protein folded properly and reached the surface.
  • The drug worked even when the mutations were far from its binding site—suggesting a universal stabilizing effect (Mighell & Lehner, 2025).

Why It’s a Big Deal

This is the first clear proof that a single drug can rescue a wide range of mutations in a human protein. If this approach works for other proteins too, it could radically change how we develop therapies for rare diseases:

  • Faster drug development: Instead of designing a drug for each mutation, we can focus on stabilizing the whole protein.
  • Better screening tools: High-throughput lab methods and sequencing can quickly find out which variants can be rescued (Matreyek et al., 2020).
  • Broader impact: Since many diseases involve protein instability, this strategy could apply to other conditions beyond NDI (Cagiada et al., 2024).

What It Means for GMDP Academy Learners

This research highlights how modern drug development relies on deep science and new technologies:

If you’re interested in cutting-edge strategies to treat rare diseases, this is a story worth following.

Get Involved

Want to lead the future of precision medicine?

🔹 Explore our CMD certification and specialized modules
🔹 Learn how to apply these innovations in real-world drug development
🔹 Join a global network of professionals shaping tomorrow’s therapiesVisit gmdpacademy.org or email us at admissions@gmdpacademy.org.

References

Bockenhauer, D., & Bichet, D. G. (2015). Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nature Reviews Nephrology, 11(10), 576–588. https://doi.org/10.1038/nrneph.2015.99

Cagiada, M., Jonsson, N., & Lindorff-Larsen, K. (2024). Decoding molecular mechanisms for loss of function variants in the human proteome. bioRxiv. https://doi.org/10.1101/2024.05.21.595203

Matreyek, K. A., Stephany, J. J., Chiasson, M. A., Hasle, N., & Fowler, D. M. (2020). An improved platform for functional assessment of large protein libraries in mammalian cells. Nucleic Acids Research, 48(1), e1. https://doi.org/10.1093/nar/gkz1025

Mighell, T. L., & Lehner, B. (2025). A small molecule stabilizer rescues the surface expression of nearly all missense variants in a GPCR. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-025-01659-6Ross, G. A., et al. (2023). The maximal and current accuracy of rigorous protein-ligand binding free energy calculations. Communications Chemistry, 6, 222. https://doi.org/10.1038/s42004-023-00973-2

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred